Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M

RHYTHM PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$2.73 revenue$14,848,000

Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).
More than 120 IMCIVREE prescriptions written for BBS since FDA approval; 40+ approved for reimbursement.
FDA Breakthrough Therapy Designation for setmelanotide in hypothalamic obesity; Phase 3 trial to start early 2023.
Completed public offering netting $131.2M; extended cash runway into 2025.
Appointed Dana Washburn as SVP Clinical Development; EC expanded approval for IMCIVREE in BBS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RHYTHM PHARMACEUTICALS, INC. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-115675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.